Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 6,000 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the completion of the transaction, the director directly owned 345,875 shares of the company’s stock, valued at approximately $79,665,388.75. This represents a 1.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded up $0.37 on Monday, hitting $236.04. 844,577 shares of the company were exchanged, compared to its average volume of 940,879. The firm has a market capitalization of $15.32 billion, a P/E ratio of 16.28, a price-to-earnings-growth ratio of 0.21 and a beta of 0.37. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a 1-year low of $128.80 and a 1-year high of $266.38. The stock’s 50 day moving average price is $247.07 and its 200 day moving average price is $229.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same period in the previous year, the company earned ($8.25) earnings per share. Jazz Pharmaceuticals’s revenue was up 15.5% on a year-over-year basis. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 21.61 EPS for the current year.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of research reports. Wall Street Zen downgraded Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Robert W. Baird raised their price target on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Morgan Stanley lifted their price objective on shares of Jazz Pharmaceuticals from $283.00 to $322.00 and gave the company an “overweight” rating in a research note on Wednesday, August 26th. Wells Fargo & Company upped their price objective on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Buy” and an average target price of $291.15.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently modified their holdings of JAZZ. Capital World Investors raised its position in shares of Jazz Pharmaceuticals by 4.4% in the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock valued at $453,322,000 after buying an additional 111,735 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after acquiring an additional 517,514 shares during the last quarter. Franklin Resources Inc. boosted its position in Jazz Pharmaceuticals by 164.0% during the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after acquiring an additional 1,129,995 shares during the last quarter. Bank of America Corp DE grew its stake in Jazz Pharmaceuticals by 10.9% during the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after acquiring an additional 99,656 shares in the last quarter. Finally, Sofinnova Investments Inc. grew its stake in Jazz Pharmaceuticals by 63.0% during the 4th quarter. Sofinnova Investments Inc. now owns 959,860 shares of the specialty pharmaceutical company’s stock valued at $163,176,000 after acquiring an additional 371,032 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.